# Comparative Study of BAT1806 to RoActemra® in Rheumatoid Arthritis Patients With Inadequate Response to Methotrexate

> **NCT03830203** · PHASE3 · COMPLETED · sponsor: **Bio-Thera Solutions** · enrollment: 621 (actual)

## Conditions studied

- Rheumatoid Arthritis

## Interventions

- **DRUG:** BAT1806
- **DRUG:** Actemra(EU-licensed)

## Key facts

- **NCT ID:** NCT03830203
- **Lead sponsor:** Bio-Thera Solutions
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-12-19
- **Primary completion:** 2021-01-05
- **Final completion:** 2021-01-05
- **Target enrollment:** 621 (ACTUAL)
- **Last updated:** 2021-11-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03830203

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03830203, "Comparative Study of BAT1806 to RoActemra® in Rheumatoid Arthritis Patients With Inadequate Response to Methotrexate". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03830203. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*